Amarantus Bioscience - AMBS.
Buy a few shares before the C.E.O.'s conference call after the close on April 16.
Buy a few shares before the company's conference call on April 17.
Most undervalued bio=tech in the market.
The following post was posted on IHub this evening by Lewsogge:
Email exchange with Gerald about latest 8k
I'm sure you're inbox and phone lines are being blown up right now, so I'll keep this brief. The increase in the O/S from ~225 million to 367 million is creating quite the stir amongst our investment group. With this new share structure AMBS' market cap is still only roughly $20,000,000 which I still consider severely undervalued. However, the unexpected increase in outstanding shares, as I'm sure you are well aware, will most likely damage the fragile relationship between yourself and cautious penny land traders who are no strangers to deceptions.
I still believe in you and the company, and understand that a start up biotech will face tough times which can require tough decisions, such as dilution. I'm sure you have a precise plan on how to best handle this and look forward to seeing it play out. May you disclose why the move to Nevada? I thought Delaware was chosen for tax purposes, or am I confusing the states?
8:57 PM (1 minute ago)
Actually not too much from other shareholders thus far. As far as the
increase, everything that we have stated is correct. We haven't
entered into financing agreements since the last Q. What has happened
specifically regarding the increase in O/S will be disclosed in our
10K filing, which will be filed in the near future as we finalize a
number of things that are meant to build value in the near-term.
While the dilution was indeed significant, what it bought the
shareholders was a much stronger company with much better prospects
for future growth, additional product lines in our diagnostics
platform and an entity that people with high repute and who are
recognized in the field are happy to be associated with. I think the
future is extremely bright from here, and agree entirely with you that
we are substantially undervalued.
The battle between all the obesity drug makers will take a while to pan out and see which drug gains more market share. But overall, I think that Arena Pharmaceuticals will be the top seller against Qsymia, because of its safety profile.
For Orexigen it is still up in the air, because they won't go up against an FDA panel for approval until 2014. Also we don't know if the "Light Study" from Orexigen will be enough to show the FDA that Contrave is safe and effective. Qsymia has started earlier in sales for now, and it still remains to be seen how successful it will be in the long run.
Arena pharmaceuticals is set to bring out Belviq sometime in 2013, and it should sell well because of its safety profile. If I had to choose one winner out of all the obesity drugs, I would choose Arena's Belviq for long-term success.
61,300,000 shares needed. :(
Now that the MANF study data has been confirmed a "big pharma" development partnership could move the share price to .50 overnight.
Noted bio-tech analyst, Jason Napadano, says that the company should be currently valued at .20/share without having attributed any value to Amarantus Diagnostics which could be generating $300,000,000 in annual revenues within three years.
The company is substantially undervalued currently.
"The Stage is Now Set for Growth: Focus on Parkinson’s and Alzheimer’s"
“We began the quarter with a strong emphasis on the Company’s lead therapeutic program: a disease-modifying treatment for Parkinson’s. As the quarter concludes we are set to announce additional animal data in that program, as well as a number of updates on other aspects of our MANF Program. Parkinson’s continues to be at the core of the Company’s plans for the future while we evaluate the value of other MANF programs, including Myocardial Infarction, Traumatic Brain Injury and Orphan diseases. We will be providing updates in regards to each of these other programs in the near future.”
“A key area of internal focus over the last quarter has been on our recently licensed LymPro Alzheimer’s Diagnostic Blood Test, which has taken on increasing importance as the role of early stage diagnostics has been further validated by the FDA’s clear guidance to pharmaceutical companies regarding the need to focus therapeutic development on early stage patients. There are a number of disease-modifying drug candidates with blockbuster potential currently in late-stage development by leading biopharmaceutical companies; LymPro would enhance those programs by providing drug developers with a better way to efficiently conduct the NDA-enabling Phase 3 clinical trials required to gain FDA approval. We are finalizing product development plans in this area."